Published in Mol Cell Ther on May 27, 2014
Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res (2016) 0.76
Characterization of sphere-forming HCT116 clones by whole RNA sequencing. Ann Surg Treat Res (2016) 0.75
Monitoring Cell-surface N-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation. Mol Cell Proteomics (2017) 0.75
The anticancer natural product ophiobolin A induces cytotoxicity by covalent modification of phosphatidylethanolamine. Elife (2016) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. Front Pharmacol (2017) 0.75
A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib. PLoS One (2017) 0.75
The sequence of the human genome. Science (2001) 101.55
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
The human ATP-binding cassette (ABC) transporter superfamily. Genome Res (2001) 5.47
NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother (1998) 4.11
Expanding mTOR signaling. Cell Res (2007) 4.01
Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res (2007) 3.72
Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 3.52
Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch (2003) 3.33
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A (2002) 3.28
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev (2006) 3.22
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta (2003) 2.53
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther (2007) 2.52
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A (2005) 2.34
Biochemical characterization of the human copper transporter Ctr1. J Biol Chem (2001) 2.28
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia (2007) 2.27
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett (2005) 2.25
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol (2000) 2.21
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica (2008) 2.18
Clinical pharmacokinetics of imatinib. Clin Pharmacokinet (2005) 2.08
Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells. Int J Pharm (2012) 2.07
Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem (1998) 2.05
hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci U S A (1997) 2.04
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos (2007) 1.97
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica (2006) 1.96
The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev (2007) 1.96
The SLC22 drug transporter family. Pflugers Arch (2003) 1.95
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem (1999) 1.87
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther (2004) 1.82
Organic cation transporters. Rev Physiol Biochem Pharmacol (2003) 1.77
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci (1998) 1.70
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics (2009) 1.62
Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem (1997) 1.62
Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney. J Biol Chem (1997) 1.60
Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet (2005) 1.57
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol (2009) 1.56
Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica (2008) 1.55
Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res (2007) 1.55
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett (1997) 1.50
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther (2000) 1.46
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos (2004) 1.45
The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med (2013) 1.45
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem (1998) 1.42
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol (2001) 1.41
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs (2000) 1.40
Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol (2007) 1.35
Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology (1997) 1.29
Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther (2003) 1.25
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem (2007) 1.22
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res (2008) 1.20
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol (2009) 1.19
In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol (2011) 1.19
cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun (1996) 1.18
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J (2009) 1.18
Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun (2001) 1.17
The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biol Ther (2012) 1.16
ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des (2014) 1.15
Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem (2006) 1.12
Role of amino acid transporters in amino acid sensing. Am J Clin Nutr (2013) 1.11
Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol (2011) 1.11
Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol (1999) 1.10
Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res (2012) 1.08
Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun (2005) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol (2010) 1.07
Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos (2008) 1.07
Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos (2008) 1.06
Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proc Natl Acad Sci U S A (2013) 1.06
Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos (2008) 1.06
Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res (2010) 1.06
An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res (1998) 1.05
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol (2005) 1.05
Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol (2006) 1.03
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther (2005) 1.03
Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther (2011) 1.03
High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res (2010) 1.03
Deletion of hepatic Ctr1 reveals its function in copper acquisition and compensatory mechanisms for copper homeostasis. Am J Physiol Gastrointest Liver Physiol (2008) 1.01
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res (2010) 1.01
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res (2003) 1.00
Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol (2008) 0.99
The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem (2009) 0.99
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Substrate recognition and translocation by polyspecific organic cation transporters. Biol Chem (2011) 0.97
Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem (2002) 0.97
Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol (2008) 0.96